We are live on ! Find out more
FSTX

F-star Therapeutics, Inc. Common Stock
FSTX

Delisted

FSTX was delisted on the 8th of March, 2023.

Back to rankings

28 hedge funds and large institutions have $2.77M invested in F-star Therapeutics, Inc. Common Stock in 2020 Q1 according to their latest regulatory filings, with 2 funds opening new positions, 7 increasing their positions, 7 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more repeat investments, than reductions

Existing positions increased: 7 | Existing positions reduced: 7

10% less funds holding

Funds holding: 31 → 28 (-3)

50% less capital invested

Capital invested by funds: $5.59M → $2.77M (-$2.82M)

60% less first-time investments, than exits

New positions opened: 2 | Existing positions closed: 5

Holders
28
Holders Change
-3
Holders Change %
-9.68%
% of All Funds
0.62%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
2
Increased
7
Reduced
7
Closed
5
Calls
$186K
Puts
–
Net Calls
+$186K
Net Calls Change
-$130K

Top Buyers

Rank Fund Capital Flow
1
Renaissance Technologies
Renaissance Technologies
New York
+$176K
2
ED
Exane Derivatives
France
+$106K
3
JP Morgan Chase
JP Morgan Chase
New York
+$42K
4
Bank of New York Mellon
Bank of New York Mellon
New York
+$38.9K
5
Acadian Asset Management
Acadian Asset Management
Massachusetts
+$33.8K

Top Sellers

Rank Fund Capital Flow
1
BBA
Baker Bros. Advisors
New York
-$969K
2
HP
Hikari Power
Japan
-$207K
3
TA
Tiedemann Advisors
New York
-$80.2K
4
Millennium Management
Millennium Management
New York
-$54.2K
5
AIM
Alambic Investment Management
California
-$16K
Name Holding Trade Value Shares
Change 		Change in
Stake
BI
1
BVF Inc
California
$885K – – –
Vanguard Group
2
Vanguard Group
Pennsylvania
$417K – – –
TA
3
Tiedemann Advisors
New York
$338K -$80.2K -15,493 -15%
Renaissance Technologies
4
Renaissance Technologies
New York
$313K +$176K +33,999 +68%
BlackRock
5
BlackRock
New York
$201K +$2.41K +465 +0.9%
PCM
6
Parsons Capital Management
Rhode Island
$77K -$12.3K -2,375 -10%
ED
7
Exane Derivatives
France
$75.9K +$106K +20,400 New
Geode Capital Management
8
Geode Capital Management
Massachusetts
$71K – – –
PCA
9
Private Capital Advisors
Connecticut
$49K – – –
SAM
10
Silvercrest Asset Management
New York
$48K – – –
JP Morgan Chase
11
JP Morgan Chase
New York
$46K +$42K +8,118 +191%
Bank of New York Mellon
12
Bank of New York Mellon
New York
$42K +$38.9K +7,511 +199%
Northern Trust
13
Northern Trust
Illinois
$37K – – –
Acadian Asset Management
14
Acadian Asset Management
Massachusetts
$31K +$33.8K +6,526 +336%
Dimensional Fund Advisors
15
Dimensional Fund Advisors
Texas
$24K +$6.32K +1,221 +23%
Morgan Stanley
16
Morgan Stanley
New York
$19K -$3.62K -700 -12%
LF
17
Lee Financial
Texas
$17K – – –
PAM
18
Pegasus Asset Management
New York
$17K – – –
CAG
19
Crestwood Advisors Group
Massachusetts
$14K – – –
Millennium Management
20
Millennium Management
New York
$11K -$54.2K -10,470 -77%
AIM
21
Arcadia Investment Management
Michigan
$11K – – –
Citadel Advisors
22
Citadel Advisors
Florida
$10K -$1.37K -265 -9%
GT
23
Glenmede Trust
Pennsylvania
$6K – – –
Victory Capital Management
24
Victory Capital Management
Texas
$6K +$7.03K +1,359 New
UBS Group
25
UBS Group
Switzerland
$4K +$5.55K +1,073 +858%
1
2

FSTX Hedge Fund Activity: Q1 2020 in Review

28 of the 4,539 institutional investors tracked by Wall St. Rank reported a position in F-star Therapeutics, Inc. Common Stock (FSTX) for Q1 2020, worth a combined $2.77M — down 50% from $5.59M a quarter earlier.

Sellers outnumbered buyers: 5 funds closed out of FSTX and 2 opened new positions — a net loss of 3 holders — while 7 trimmed existing stakes and 7 added.

The largest buyer was Renaissance Technologies, adding an estimated $176K. The largest seller was Baker Bros. Advisors, exiting entirely with an estimated $969K sold.

  • 28 institutional investors held F-star Therapeutics, Inc. Common Stock (FSTX) as of Q1 2020, down from 31 in Q4 2019.
  • Funds reported $2.77M of F-star Therapeutics, Inc. Common Stock stock for Q1 2020, down 50% quarter-over-quarter.
  • 2 funds opened new F-star Therapeutics, Inc. Common Stock positions in Q1 2020 and 5 closed out, a net change of -3 holders.
  • The largest F-star Therapeutics, Inc. Common Stock buyer in Q1 2020 was Renaissance Technologies, an estimated $176K added.
  • The largest F-star Therapeutics, Inc. Common Stock seller in Q1 2020 was Baker Bros. Advisors, an estimated $969K sold.

Based on aggregated 13F filings for Q1 2020.